NVO logo

Novo Nordisk A/S (NVO) Depreciation and amortization

annual D&A:

$1.24B-$126.85M(-9.28%)
December 31, 2024

Summary

  • As of today (May 31, 2025), NVO annual depreciation & amortization is $1.24 billion, with the most recent change of -$126.85 million (-9.28%) on December 31, 2024.
  • During the last 3 years, NVO annual D&A has risen by +$281.08 million (+29.32%).
  • NVO annual D&A is now -9.28% below its all-time high of $1.37 billion, reached on December 31, 2023.

Performance

NVO Depreciation and amortization Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVOincome statement metrics

quarterly D&A:

$539.97M+$1.35B(+166.66%)
March 31, 2025

Summary

  • As of today (May 31, 2025), NVO quarterly depreciation & amortization is $539.97 million, with the most recent change of +$1.35 billion (+166.66%) on March 31, 2025.
  • Over the past year, NVO quarterly D&A has increased by +$115.52 million (+27.22%).
  • NVO quarterly D&A is now -57.58% below its all-time high of $1.27 billion, reached on June 30, 2024.

Performance

NVO quarterly D&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVOincome statement metrics

TTM D&A:

$1.36B+$115.52M(+9.32%)
March 31, 2025

Summary

  • As of today (May 31, 2025), NVO TTM depreciation & amortization is $1.36 billion, with the most recent change of +$115.52 million (+9.32%) on March 31, 2025.
  • Over the past year, NVO TTM D&A has dropped by -$187.87 million (-12.17%).
  • NVO TTM D&A is now -45.67% below its all-time high of $2.49 billion, reached on June 30, 2024.

Performance

NVO TTM D&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVOincome statement metrics

NVO Depreciation and amortization Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-9.3%+27.2%-12.2%
3 y3 years+29.3%+116.9%+37.7%
5 y5 years+46.1%+236.8%+59.8%

NVO Depreciation and amortization Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-9.3%+29.3%-57.6%+166.7%-45.7%+37.7%
5 y5-year-9.3%+46.1%-57.6%+166.7%-45.7%+65.4%
alltimeall time-9.3%+1370.6%-57.6%+166.7%-45.7%+1174.1%

NVO Depreciation and amortization History

DateAnnualQuarterlyTTM
Mar 2025
-
$539.97M(-166.7%)
$1.36B(+9.3%)
Dec 2024
$1.24B(-9.3%)
-$810.01M(-329.8%)
$1.24B(-50.0%)
Sep 2024
-
$352.45M(-72.3%)
$2.48B(-0.6%)
Jun 2024
-
$1.27B(+199.9%)
$2.49B(+61.7%)
Mar 2024
-
$424.45M(-1.1%)
$1.54B(+12.9%)
Dec 2023
$1.37B(+30.9%)
$428.96M(+16.5%)
$1.37B(+8.5%)
Sep 2023
-
$368.27M(+14.5%)
$1.26B(+10.3%)
Jun 2023
-
$321.51M(+29.7%)
$1.14B(+9.6%)
Mar 2023
-
$247.90M(-23.1%)
$1.04B(-0.1%)
Dec 2022
$1.04B(+8.9%)
$322.46M(+28.6%)
$1.04B(-1.1%)
Sep 2022
-
$250.76M(+13.2%)
$1.05B(+4.6%)
Jun 2022
-
$221.52M(-11.0%)
$1.01B(+2.5%)
Mar 2022
-
$248.91M(-25.4%)
$984.39M(+2.7%)
Dec 2021
$958.70M(+8.8%)
$333.58M(+62.9%)
$958.70M(+17.0%)
Sep 2021
-
$204.74M(+3.8%)
$819.48M(-15.6%)
Jun 2021
-
$197.17M(-11.7%)
$970.47M(+2.8%)
Mar 2021
-
$223.22M(+14.9%)
$944.37M(+7.1%)
Dec 2020
$881.48M(+3.8%)
$194.35M(-45.4%)
$881.48M(-2.2%)
Sep 2020
-
$355.73M(+107.9%)
$900.90M(+5.5%)
Jun 2020
-
$171.07M(+6.7%)
$854.05M(+0.7%)
Mar 2020
-
$160.33M(-25.0%)
$848.14M(-0.1%)
Dec 2019
$848.83M(+36.5%)
$213.78M(-30.8%)
$848.83M(-5.8%)
Sep 2019
-
$308.88M(+87.0%)
$900.78M(+27.3%)
Jun 2019
-
$165.15M(+2.6%)
$707.57M(+6.9%)
Mar 2019
-
$161.02M(-39.4%)
$662.01M(+6.5%)
Dec 2018
$621.75M(+28.4%)
$265.73M(+129.7%)
$621.75M(+29.4%)
Sep 2018
-
$115.67M(-3.3%)
$480.52M(-2.4%)
Jun 2018
-
$119.59M(-1.0%)
$492.41M(-2.2%)
Mar 2018
-
$120.76M(-3.0%)
$503.68M(+4.0%)
Dec 2017
$484.35M(+2.1%)
$124.50M(-2.4%)
$484.35M(-7.4%)
Sep 2017
-
$127.56M(-2.5%)
$523.00M(+3.9%)
Jun 2017
-
$130.86M(+29.0%)
$503.31M(+4.0%)
Mar 2017
-
$101.43M(-37.8%)
$483.77M(+1.9%)
Dec 2016
$474.60M(+7.8%)
$163.16M(+51.3%)
$474.60M(+2.7%)
Sep 2016
-
$107.86M(-3.1%)
$462.16M(+2.8%)
Jun 2016
-
$111.32M(+20.7%)
$449.68M(+4.1%)
Mar 2016
-
$92.26M(-38.8%)
$432.06M(-1.9%)
DateAnnualQuarterlyTTM
Dec 2015
$440.22M(-28.1%)
$150.72M(+58.0%)
$440.22M(-3.5%)
Sep 2015
-
$95.39M(+1.8%)
$456.38M(-19.0%)
Jun 2015
-
$93.70M(-6.7%)
$563.48M(-4.9%)
Mar 2015
-
$100.42M(-39.8%)
$592.48M(-3.3%)
Dec 2014
$612.67M(+22.9%)
$166.88M(-17.6%)
$612.67M(+37.4%)
Sep 2014
-
$202.48M(+65.0%)
$445.79M(+83.2%)
Jun 2014
-
$122.70M(+1.7%)
$243.31M(+101.7%)
Mar 2014
-
$120.61M(-7.3%)
$120.61M(-72.5%)
Dec 2013
$498.39M(+7.2%)
-
-
Dec 2012
$465.06M(-9.0%)
-
-
Dec 2011
$511.28M(+16.4%)
-
-
Dec 2010
$439.19M(-8.0%)
$130.11M(+20.3%)
$439.19M(-0.5%)
Sep 2010
-
$108.18M(+16.5%)
$441.31M(-6.0%)
Jun 2010
-
$92.87M(-14.0%)
$469.71M(-2.0%)
Mar 2010
-
$108.03M(-18.3%)
$479.08M(+0.3%)
Dec 2009
$477.42M(-1.1%)
$132.23M(-3.2%)
$477.42M(+38.3%)
Sep 2009
-
$136.58M(+33.6%)
$345.19M(+65.5%)
Jun 2009
-
$102.23M(-3.9%)
$208.61M(+96.1%)
Mar 2009
-
$106.37M
$106.37M
Dec 2008
$482.62M(-12.9%)
-
-
Dec 2007
$553.92M(+53.6%)
-
-
Dec 2006
$360.68M(+11.9%)
-
-
Dec 2005
$322.20M(+1.2%)
-
-
Dec 2004
$318.50M(+28.7%)
-
-
Dec 2003
$247.53M(+46.2%)
-
-
Dec 2002
$169.32M(+30.7%)
-
-
Dec 2001
$129.52M(+1.0%)
-
-
Dec 2000
$128.25M(-5.5%)
-
-
Dec 1999
$135.72M(-8.0%)
-
-
Dec 1998
$147.55M(-14.8%)
-
-
Dec 1997
$173.21M(-5.9%)
-
-
Dec 1996
$184.13M(-9.5%)
-
-
Dec 1995
$203.43M(+22.3%)
-
-
Dec 1994
$166.28M(+34.7%)
-
-
Dec 1993
$123.41M(+7.1%)
-
-
Dec 1992
$115.18M(+24.1%)
-
-
Dec 1991
$92.79M(+10.1%)
-
-
Dec 1990
$84.30M
-
-

FAQ

  • What is Novo Nordisk A/S annual depreciation & amortization?
  • What is the all time high annual D&A for Novo Nordisk A/S?
  • What is Novo Nordisk A/S annual D&A year-on-year change?
  • What is Novo Nordisk A/S quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for Novo Nordisk A/S?
  • What is Novo Nordisk A/S quarterly D&A year-on-year change?
  • What is Novo Nordisk A/S TTM depreciation & amortization?
  • What is the all time high TTM D&A for Novo Nordisk A/S?
  • What is Novo Nordisk A/S TTM D&A year-on-year change?

What is Novo Nordisk A/S annual depreciation & amortization?

The current annual D&A of NVO is $1.24B

What is the all time high annual D&A for Novo Nordisk A/S?

Novo Nordisk A/S all-time high annual depreciation & amortization is $1.37B

What is Novo Nordisk A/S annual D&A year-on-year change?

Over the past year, NVO annual depreciation & amortization has changed by -$126.85M (-9.28%)

What is Novo Nordisk A/S quarterly depreciation & amortization?

The current quarterly D&A of NVO is $539.97M

What is the all time high quarterly D&A for Novo Nordisk A/S?

Novo Nordisk A/S all-time high quarterly depreciation & amortization is $1.27B

What is Novo Nordisk A/S quarterly D&A year-on-year change?

Over the past year, NVO quarterly depreciation & amortization has changed by +$115.52M (+27.22%)

What is Novo Nordisk A/S TTM depreciation & amortization?

The current TTM D&A of NVO is $1.36B

What is the all time high TTM D&A for Novo Nordisk A/S?

Novo Nordisk A/S all-time high TTM depreciation & amortization is $2.49B

What is Novo Nordisk A/S TTM D&A year-on-year change?

Over the past year, NVO TTM depreciation & amortization has changed by -$187.87M (-12.17%)
On this page